Clorox Reports Fiscal 2025 Net Sales of $7.1 Billion; EPS Misses Guidance

Reuters
2025/08/09
Clorox Reports Fiscal 2025 Net Sales of $7.1 Billion; EPS Misses Guidance

The Clorox Company reported its financial results for fiscal year 2025, with net sales amounting to $7.1 billion, remaining essentially flat compared to the previous year. Despite macroeconomic uncertainties and changes in shopping behaviors leading to temporary category slowdowns, the company achieved organic sales and earnings growth. Clorox successfully expanded its overall market share and increased its gross margin during this period. A significant highlight for the company was a 190% increase in diluted net earnings per share $(EPS)$ compared to the prior fiscal year. This improvement was largely attributed to several factors, including losses associated with the divestiture of the Argentina business in the previous year, higher volume in the current period, and cost savings. Additionally, the benefits from cyberattack insurance recoveries contributed positively to the results, although these were partially offset by the loss related to another divestiture. The Clorox Company, with about 7,600 employees worldwide, continues to focus on building a stronger, more resilient business. The company operates in approximately 25 countries or territories and sells its products in around 100 markets globally, through various retail channels and e-commerce platforms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Clorox Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000021076-25-000039), on August 08, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10